The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

doi:10.1111/exd.14446

Review

. 2021 Oct;30(10):1517-1531.

doi: 10.1111/exd.14446. Epub 2021 Aug 24.

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Harri Alenius^{1

2}, Hanna Sinkko^{1

2}, Lucas Moitinho-Silva^{3

4}, Elke Rodriguez³, Conor Broderick⁵, Helen Alexander⁵, Matthias Reiger^{6

7

8}, Mathis Hjort Hjelmsø⁹, Nanna Fyhrquist¹, Peter Olah^{10

11}, Paul Bryce¹², Catherine Smith¹³, Frits Koning¹⁴, Kilian Eyerich¹⁵, Dario Greco^{16

17}, Ellen H van den Bogaard¹⁸, Avidan U Neumann^{6

7}, Claudia Traidl-Hoffmann^{6

7

8

19

20}, Bernhard Homey¹⁰, Carsten Flohr²¹, Klaus Bønnelykke⁹, Jakob Stokholm^{9

22}, Stephan Weidinger³

Affiliations

¹ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
² Human Microbiome Research Program (HUMI), Faculty of Medicine, University of Helsinki, Helsinki, Finland.
³ Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
⁴ Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
⁵ Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
⁶ Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
⁷ Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany.
⁸ Chair of Environmental Medicine, Technical University Munich, Munich, Germany.
⁹ COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
¹⁰ Department of Dermatology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
¹¹ Department of Dermatology, Venereology and Oncodermatology, Medical Faculty, University of Pécs, Pécs, Hungary.
¹² Type 2 Inflammation & Fibrosis Cluster, Immunology & Inflammation Therapeutic Area, Sanofi US, Cambridge, Massachusetts, USA.
¹³ Kings College London, and Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, St John's Institute of Dermatology, London, UK.
¹⁴ Department of Immunology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands.
¹⁵ Department of Medicine, Karolinska Institutet, Solna, Sweden.
¹⁶ Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
¹⁷ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
¹⁸ Department of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
¹⁹ CK CARE, Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
²⁰ ZIEL - Institute for Food & Health, Technical University of Munich, Freising-Weihenstephan, Germany.
²¹ Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.
²² Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.

PMID: 34387406
DOI: 10.1111/exd.14446

Review

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Harri Alenius et al. Exp Dermatol. 2021 Oct.

. 2021 Oct;30(10):1517-1531.

doi: 10.1111/exd.14446. Epub 2021 Aug 24.

Authors

Affiliations

¹ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
² Human Microbiome Research Program (HUMI), Faculty of Medicine, University of Helsinki, Helsinki, Finland.
³ Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
⁴ Institute of Clinical Molecular Biology, Kiel University, Kiel, Germany.
⁵ Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
⁶ Department of Environmental Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
⁷ Institute of Environmental Medicine, Helmholtz Zentrum München, Augsburg, Germany.
⁸ Chair of Environmental Medicine, Technical University Munich, Munich, Germany.
⁹ COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
¹⁰ Department of Dermatology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
¹¹ Department of Dermatology, Venereology and Oncodermatology, Medical Faculty, University of Pécs, Pécs, Hungary.
¹² Type 2 Inflammation & Fibrosis Cluster, Immunology & Inflammation Therapeutic Area, Sanofi US, Cambridge, Massachusetts, USA.
¹³ Kings College London, and Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, St John's Institute of Dermatology, London, UK.
¹⁴ Department of Immunology, Leiden University Medical Centre (LUMC), Leiden, the Netherlands.
¹⁵ Department of Medicine, Karolinska Institutet, Solna, Sweden.
¹⁶ Institute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
¹⁷ Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
¹⁸ Department of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
¹⁹ CK CARE, Christine Kühne Center for Allergy Research and Education, Davos, Switzerland.
²⁰ ZIEL - Institute for Food & Health, Technical University of Munich, Freising-Weihenstephan, Germany.
²¹ Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, School of Basic and Medical Biosciences, King's College London, London, UK.
²² Department of Food Science, University of Copenhagen, Frederiksberg, Denmark.

PMID: 34387406
DOI: 10.1111/exd.14446

Abstract

The two most common chronic inflammatory skin diseases are atopic dermatitis (AD) and psoriasis. The underpinnings of the remarkable degree of clinical heterogeneity of AD and psoriasis are poorly understood and, as a consequence, disease onset and progression are unpredictable and the optimal type and time point for intervention are as yet unknown. The BIOMAP project is the first IMI (Innovative Medicines Initiative) project dedicated to investigating the causes and mechanisms of AD and psoriasis and to identify potential biomarkers responsible for the variation in disease outcome. The consortium includes 7 large pharmaceutical companies and 25 non-industry partners including academia. Since there is mounting evidence supporting an important role for microbial exposures and our microbiota as factors mediating immune polarization and AD and psoriasis pathogenesis, an entire work package is dedicated to the investigation of skin and gut microbiome linked to AD or psoriasis. The large collaborative BIOMAP project will enable the integration of patient cohorts, data and knowledge in unprecedented proportions. The project has a unique opportunity with a potential to bridge and fill the gaps between current problems and solutions. This review highlights the power and potential of the BIOMAP project in the investigation of microbe-host interplay in AD and psoriasis.

Keywords: atopic dermatitis; biomarkers; microbiome; psoriasis.

PubMed Disclaimer

Cited by

State of the Art on the Role of Staphylococcus aureus Extracellular Vesicles in the Pathogenesis of Atopic Dermatitis.
Torrealba MP, Yoshikawa FSY, Aoki V, Sato MN, Orfali RL. Torrealba MP, et al. Microorganisms. 2024 Mar 6;12(3):531. doi: 10.3390/microorganisms12030531. Microorganisms. 2024. PMID: 38543582 Free PMC article. Review.
Emollients "Plus" are Beneficial in Both the Short and Long Term in Mild Atopic Dermatitis.
Cestari S, Correia P, Kerob D. Cestari S, et al. Clin Cosmet Investig Dermatol. 2023 Aug 8;16:2093-2102. doi: 10.2147/CCID.S417622. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 37575149 Free PMC article.
The interrelation of scientific, ethical, and translational challenges for precision medicine with multimodal biomarkers - A qualitative expert interview study in dermatology research.
Hangel N, Buyx A, Fritzsche MC. Hangel N, et al. Heliyon. 2024 Jun 24;10(13):e31723. doi: 10.1016/j.heliyon.2024.e31723. eCollection 2024 Jul 15. Heliyon. 2024. PMID: 39040296 Free PMC article.
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases.
Vetrano S, Bouma G, Benschop RJ, Birngruber T, Costanzo A, D'Haens GRAM, Frasca L, Hillenbrand R, Iversen L, Johansen C, Kaser A, Koenen HJPM, Noehammer C, Peyrin-Biroulet L, Raes J, Ricotti L, Rosenstiel P, Satagopam VP, Schreiber S, Vermeire S, Wollenberg A, Weidinger S, Ziemek D, Danese S; ImmUniverse Consortium. Vetrano S, et al. Front Immunol. 2022 Nov 9;13:1002629. doi: 10.3389/fimmu.2022.1002629. eCollection 2022. Front Immunol. 2022. PMID: 36439150 Free PMC article.
Targeting Skin Barrier Function in Atopic Dermatitis.
van den Bogaard EH, Elias PM, Goleva E, Berdyshev E, Smits JPH, Danby SG, Cork MJ, Leung DYM. van den Bogaard EH, et al. J Allergy Clin Immunol Pract. 2023 May;11(5):1335-1346. doi: 10.1016/j.jaip.2023.02.005. Epub 2023 Feb 19. J Allergy Clin Immunol Pract. 2023. PMID: 36805053 Free PMC article.

References

REFERENCES

1. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622.
1. Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983-994.
1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.
1. Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information

[1] Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622.

[2] Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA. 2004;291(21):2616-2622.

[3] Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983-994.

[4] Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983-994.

[5] Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.

[6] Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360.

[7] Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.

[8] Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.

[9] Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.

[10] Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1527-1534.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Affiliations

The power and potential of BIOMAP to elucidate host-microbiome interplay in skin inflammatory diseases

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical